Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email:


FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.

European Commission Approves Pembrolizumab Plus Chemotherapy for High-Risk Early-Stage TNBC

May 24th 2022

The European Commission approved pembrolizumab for use in combination with chemotherapy as neoadjuvant therapy, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma

May 20th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

FDA Grants Breakthrough Designation to Repotrectinib for Pretreated, ROS1+ Metastatic NSCLC

May 11th 2022

The FDA has granted a breakthrough therapy designation to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer who have been previously treated with one ROS1 TKI and have not received prior platinum-based chemotherapy.

Breast Cancer Paradigm Pushes Forward With Neoadjuvant, Adjuvant Advances

May 2nd 2022

Reshma Mahtani, DO, discusses the use of antibody-drug conjugates, tyrosine kinase inhibitors, CDK4/6 inhibitors, and PARP inhibitors across HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

European Commission Approves Pembrolizumab for Select MSI-H/dMMR Solid Tumors

April 29th 2022

The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.

Genomics Guide Treatment, But Novel Agents Generate Excitement in AML and HR-MDS

April 28th 2022

New data ranging from up-front approaches with targeted therapy to maintenance therapy, as well as emerging findings with novel agents continue to push the paradigm forward in acute myeloid leukemia and higher-risk myelodysplastic syndromes.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

April 27th 2022

The FDA has granted a breakthrough therapy designation to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Novel Gene Signature Found in Cutaneous Chronic GVHD Responders to Topical Ruxolitinib

April 24th 2022

A differentially expressed gene profile was identified in patients with cutaneous nonsclerotic and superficially sclerotic chronic graft-vs-host-disease who responded to treatment with topical ruxolitinib.

FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2022

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

FDA Grants Priority Review to Trastuzumab Deruxtecan for Previously Treated HER2-Mutant NSCLC

April 19th 2022

The FDA has accepted for priority review a supplemental biologics license application for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

Pepinemab Plus Pembrolizumab Promotes Antitumor Activity in Recurrent/Metastatic Head and Neck Cancer

April 11th 2022

The combination of pepinemab and pembrolizumab elicited encouraging responses and tolerability as frontline therapy in patients with recurrent or metastatic head and neck cancer.

Movement of Novel Agents Up Front Is Current Focus in Hematologic Cancers

April 6th 2022

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

MRD-Guided Treatment Approaches Under Study Across Hematologic Malignancies

March 31st 2022

Shaji K. Kumar, MD, discusses key takeaways from each presentation on chronic lymphocytic leukemia, myelofibrosis, relapsed/refractory diffuse large B-cell lymphoma, CAR T-cell therapy, and multiple myeloma.

New Treatment Standards Spark Questions About De-escalation and Sequencing in Breast Cancer

March 30th 2022

Sara M. Tolaney, MD, MPH, reviews practice-changing data sets throughout breast cancer and provides perspective on potential treatment approaches in the absence of definitive results.

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

March 29th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Breast Cancer Treatment Advances Lead to Broadened Scope of Personalized Medicine

March 21st 2022

Harold J. Burstein, MD, PhD, discusses treatment updates across HER2-positive breast cancer, adjuvant advances in estrogen receptor–positive disease, and the domino effect of immunotherapy in triple-negative breast cancer.